We are live on ! Find out more
AC

Armistice Capital Portfolio holdings

AUM $5.62B
1-Year Est. Return 36.06%
This Fund
S&P 500
This Quarter Est. Return
+15.6%
1 Year Est. Return
+36.06%
3 Year Est. Return
+44.14%
5 Year Est. Return
+38.37%
10 Year Est. Return
+188.88%
AUM
$8.4B
AUM Growth
+$1.66B
Cap. Flow
+$1.33B
Cap. Flow %
15.85%
Top 10 Hldgs %
61.33%
Holding
510
New
182
Increased
113
Reduced
52
Closed
146

Top Buys

Rank Stock Value
1
AGIO icon
Agios Pharmaceuticals
AGIO
+$79.7M
2
MDGL icon
Madrigal Pharmaceuticals
MDGL
+$74.4M
3
KVUE icon
Kenvue
KVUE
+$65.3M
4
ELF icon
e.l.f. Beauty
ELF
+$51.7M
5
GSK icon
GSK
GSK
+$46.6M

Sector Composition

Rank Sector Weight
1 Healthcare 32.56%
2 Technology 5.44%
3 Consumer Discretionary 5.13%
4 Consumer Staples 2.69%
5 Communication Services 1.68%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake
Capital Flow
VIK icon
501
Viking Holdings
VIK
$47.2B
-19,042
Closed -$1.18M
CNH
502
CNH Industrial
CNH
$17.5B
-27,236
Closed -$296K
DGNX
503
Diginex Ltd
DGNX
$44.2M
-1,250
Closed -$144K
SFD
504
Smithfield Foods
SFD
$9.99B
-28,707
Closed -$674K
CHYM
505
Chime Financial
CHYM
$11.1B
-12,722
Closed -$257K
OTF
506
Blue Owl Technology Finance Corp
OTF
$5.36B
-17,712
Closed -$245K
AMRZ
507
Amrize Ltd
AMRZ
$25.8B
-7,929
Closed -$385K
RAL
508
Ralliant Corp
RAL
$7.46B
-7,039
Closed -$308K
FLY
509
Firefly Aerospace
FLY
$4.39B
-6,839
Closed -$201K
KYIV
510
Kyivstar Group
KYIV
$3.09B
-12,301
Closed -$154K

Similar funds

Armistice Capital's Q4 2025 Portfolio in Review

As of Q4 2025, Armistice Capital held 510 positions worth $8.4B, up 25% from $6.74B the previous quarter. Its ten largest holdings account for 61% of the portfolio.

Armistice Capital deployed $1.33B of net new capital in Q4 2025, opening 182 new positions and adding to 113 existing holdings. Its largest new stake was Kenvue: 3,992,196 shares worth $68.9M.

By sector, the portfolio is most concentrated in Healthcare at 33% of assets, up from 32% a quarter earlier, followed by Technology and Consumer Discretionary.

On the sell side, the largest reduction was Travere Therapeutics, an estimated $96.3M trimmed.

  • Armistice Capital's largest Q4 2025 buy was Kenvue: 3,992,196 shares worth $68.9M.
  • Armistice Capital added most to Agios Pharmaceuticals in Q4 2025, an estimated $79.7M increase.
  • Armistice Capital's biggest Q4 2025 reduction was Travere Therapeutics, cutting an estimated $96.3M.
  • Armistice Capital fully exited Exact Sciences in Q4 2025, selling an estimated $56.4M.
  • Armistice Capital's ten largest holdings make up 61% of its $8.4B portfolio in Q4 2025.
  • Armistice Capital opened 182 new positions and closed 146 in Q4 2025.
  • Armistice Capital's portfolio value rose 25% quarter-over-quarter to $8.4B.

Based on Armistice Capital's 13F filing for Q4 2025, filed 17 Feb 2026.